Minimally invasive treatment for benign prostatic hyperplasia

Current Opinion in Urology

Volumn 8, Issue 1, 1998, Pages 17-26

  Madersbacher, Stephan ^a   Djavan, Bob ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTROSURGERY; ENERGY RESOURCE; HOLMIUM LASER; HUMAN; LASER COAGULATION; LASER SURGERY; MALE; MICROWAVE IRRADIATION; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RADIOFREQUENCY; REVIEW; SURGICAL TECHNIQUE; ULTRASOUND;

EID: 0031974486     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199801000-00004     Document Type: Review

References (64)

1. Bernier PA, Roehrborn CG. Thermal therapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 1997; 7:15-20. Latest review regarding microwave thermotherapy in Current Opinion in Urology.
2. De la Rosette JJMCH, D'Ancona FCH, Debruyne FMJ. Current status of thermotherapy of the prostate. J Urol 1997; 157:430-438. Extensive review on low- and high-energy microwave thermotherapy.
3. Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy v sham treatment: double blind randomised study. J Endourol 1996; 10:565-573.
4. Nawrocki JD, Bell TJ, Lawrence WT, Ward JP. A randomized controlled trial of transurethral microwave thermotherapy. Br J Urol 1997; 79:389-393. Using a tricky study design, the authors challenge previous sham-controlled studies regarding TUMT 2.0; only patients with urodynamically proven BOO were eligible.
5. Hallin A, Berlin T. Transurethral microwave thermotherapy of benign prostatic hyperplasia: do any pretreatment conditions predict the result? Eur Urol 1996; 30:429-436.
6. De Wildt MJAM, D'Ancona FCH, Hubregtse M, Carter SSC, Debruyne FMJ, de la Rosette JJMCH. Three-year follow-up of patients treated with lower energy microwave thermotherapy. J Urol 1996; 156:1959-1963. Within three years after low-energy TUMT, 31% underwent invasive procedures and a further 23% received medical therapy.
7. Dawkins GPC, Harrison NW, Ansell W. Radiofrequency heat-treatment to the prostate for bladder outlet obstruction associated with benign prostatic hyperplasia: a 4-year outcome study. Br J Urol 1997; 79:910-914.
8. Daehlin L, Frugard J. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: one-year's results with the PRIMUS U + R device. Scand J Urol Nephrol 1997; 31:57-61.
9. D'Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, de la Rosette JJMCH. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of follow-up. J Urol 1997; 158:120-125. Efficacy of high-energy TUMT is demonstrated in this RCT. Compared with TUR/P. symptomatic improvement is similar: objective parameters, however. increased more after TUR/P.
10. Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997; 79:181-185. In contrast to [9**], this study failed to demonstrate the efficacy of high-energy TUMT to improve objective parameters: only patients with urodynamically proven BOO were eligible.
11. De la Rosette JJMCH, de Wildt MJAM, Höfner K, Carter SSC, Debruyne FMJ, Tubaro A. High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European benign prostatic hyperplasia group. J Urol 1996; 156:97-102. This multi-centre trial demonstrates the efficacy of high-energy TUMT.
12. De Wildt MJ, Debruyne FM, de la Rosette JJ. High-energy transurethral microwave-thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996; 48:416-423.
13. Ramsey EW, Miller PD, Parsons K. A novel transurethral microwave thermal ablation system to treat benign prostatic hyperplasia: results of a prospective multicenter clinical trial. J Urol 1997; 158:112-119. The largest clinical study available for the T3 device, demonstrating the efficacy and safety of this high-energy TUMT system.
14. Javle P, Blair M, Palmer M, Jenkins SA, Parsons KF. The role of an advanced thermotherapy device in prostatic voiding dysfunction. Br J Urol 1996; 78:391-397.
15. Almer FM, Fretschner M, Harzmann R, Altwein JE. Transurethrale Mikrowellen-Thermotherapie. Akt Urol 1996; 27:275-280.
16. Dahlstrand C, Grundtman S, Pettersson S. High-energy transurethral microwave thermotherapy for large severely obstructing prostates and the use of biodegradable stents to avoid catheterization after treatment. Br J Urol 1997; 79:907-909.
17. De la Rosette JJMCH, de Wildt MJAM, Höfner K, Carter SSC, Debruyne FMJ, Tubaro A. Pressure-flow study analyses in patients treated with high energy thermotherapy. J Urol 1996; 156:1428-1433. High-energy TUMT results in a significant and substantial decrease in bladder outflow obstruction.
18. Issa MM, Oesterling JE. Transurethral needle ablation (TUNA): an overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia. Curr Opin Urol 1996; 6:20-27.
19. Zlotta AR, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanism of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol 1997; 157:894-899.
20. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997; 49:847-850.
21. Issa MM. Transurethral needle ablation of the prostate: report of initial United States experience. J Urol 1996; 156:413-419.
22. Millard RJ, Harewood LM, Tamaddon K. A study of the efficacy and safety of transurethral needle ablation (TUNA®) treatment for benign prostatic hyperplasia. Neurourol Urodyn 1996; 15:619-629.
23. max is more profound after TUR/P.
24. Virdi JS, Pandit A, Sriram R. Transurethral needle ablation of the prostate: a prospective study with a 2-year follow-up [Abstract]. Br J Urol 1997; 78 (Suppl4):61. The second RCT available comparing TUNA to TUR/P. Similar results as reported In [23*].
25. max following interstitial radiofrequency therapy is less pronounced than after TUR/P.
26. Madersbacher S, Marberger M. High-intensity focused ultrasound for prostatic tissue ablation. Curr Opin Urol 1996; 6:28-32. Latest review in Current Opinion in Urology on this issue with a detailed description of the transducer design, treatment technique, histological and clinical data for prostatic tissue ablation by HIFU.
27. Nakamura K, Baba S, Saito S, Tachibana M, Murai M. Improvement of clinical response by high intensity focused ultrasound for benign prostatic hyperplasia using Sonablate 200 [Abstract]. J Urol 1997; 157:433.
28. Mulligan ED, Lynch TH, Mulvin D, Greene D, Smith JM, Fitzpatrick JM. High-intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br J Urol 1997; 79:177-180.
29. Madersbacher S, Klingler CH, Schatzl G, Schmidbauer CP, Marberger M. The urodynamlc impact of transrectal high intensity focused ultrasound on bladder outflow obstruction. Eur Urol 1996; 30:437-445.
30. Sullivan LD, McLoughlin MG, Goldenberg LG, Gleave ME, Marich KW. Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hyperplasia. Br J Urol 1997; 79:172-176.
31. Te Slaa E, de la Rosette JJMCH. Lasers in the treatment of benign prostatic obstruction: past, present, and future. Eur Urol 1996; 30:1-10. Extensive review on laser prostatectomy.
32. Kabalin JN. Laser prostatectomy. Curr Opin Urol 1997; 7:37-43.
33. max increase after VLAP reported in this study is relatively small.
34. Sengör F, Köse O, Yücebas E, Beysel M, Erdogan K, Narter F. A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-month follow-up. Br J Urol 1996; 78:398-400.
35. Narayan P, Tewari A, Schalow E, Leidich R, Aboseif S, Cascione C. Transurethral evaporisation of the prostate for treatment of benign prostatic hyperplasia: results in 168 patients with up to 12 months follow-up. J Urol 1997; 157:1309-1312.
36. Jung P, Mattelear P, Wolff JM, Mersdorf A, Jakse G. Visual laser ablation of the prostate: efficacy evaluated by urodynamics and compared to TURP. Eur Urol 1996; 30:418-423. In this prospective study, 80% of patients with prostates >50 ml remained obstructed postoperatively and 30% required re-therapy within three months after initial VLAP.
37. Kabalin JN, Gill HS, Leach GE, Bowers GW, Nill T, Konowalchuk TW. Prospective multicenter prolase II clinical trial of neodymium:yttrium-aluminum-garnet laser prostatectomy. Urology 1997; 50:63-65.
38. Lorge FJ, Nesa S, Wese FX, van Cangh PJ. Efficacy of laser prostatectomy at 2 year's follow-up. J Endourol 1996; 10:449-451.
39. Kollmorgen TA, Malek RS, Barrett DM. Laser prostatectomy: two and a half years' experience with aggressive multifocal therapy. Urology 1996; 48:217-222.
40. Flynn RJ, de Souza NM, Puni R, Williams G, Kiely EA. Endoscopic laser ablation of the prostate (ELAP): changes in magnetic resonance imaging and clinical outcome at 1 year. Br J Urol 1996; 78:747-751.
41. Miller J, Erkens U, Fischer C, Klotzer JP, Weidner W. Transurethral laser ablation of the prostate in high risk patients with obstructive benign prostatic hyperplasia. Perioperative morbidity and 6 month in 72 patients. Urologe [A] 1997; 36:165-172.
42. Farsi HM. Visual laser ablation of the prostate for patients with acute urinary retention. Br J Urol 1996; 78:90-92.
43. Puri R, Smaling A, Lloyd SN. A randomized study of visual laser ablation of the prostate and TURP: the ugly truth [Abstract]. Br J Urol 1997; 79 (Suppl 4):61. In this RCT, 10% of patients underwent re-therapy within one year and BOO was demonstrable in 50% of patients after VLAP.
44. Petas A, Talja M, Tammela T, Taari K, Lehtoranta K, Valimaa T. Tormala P. A randomized study to compare biodegradable self-reinforced polyglycolic acid spiral stents to suprapubic and indwelling catheters after visual laser ablation of the prostate. J Urol 1997; 157:173-176.
45. Schatzl G, Madersbacher S, Lang T, Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally Invasive treatment alternatives. J Urol 1997; 158:105-111. A single-centre experience comparing efficacy and morbidity of TUR/P to four minimally invasive treatment options; postoperative morbidity was assessed in detail by a patient-addressed diary-type questionnaire.
46. Muschter R. Interstitial laser therapy. Curr Opin Urol 1996; 6:33-38. A thorough introduction into ILC including the theoretical background and preliminary clinical results.
47. Muschter R, de la Rosette JJ, Whitfield H, Pellerin JP, Madersbacher S, Gillatt D. Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. Urology 1996; 48:223-226.
48. Aral Y, Ishitoya S, Okubo K, Suzuki Y. Transurethral interstitial laser coagulation for benign prostatic hyperplasia: treatment outcome and quality of life. Br J Urol 1996; 78:93-98.
49. Horninger W, Janetschek G, Watson G, Reissigl A, Strasser H, Bartsch G. Are contact laser, interstitial laser, and transurethral ultrasound-guided laser-induced prostatectomy superior to transurethral prostatectomy? Prostate 1997; 31:255-263.
50. Te AE, Kaplan SA. Transurethral electrovaporisation of the prostate: the year in review. Curr Opin Urol 1997; 7:25-36.
51. Thomas KJ, Cornaby AJ, Hammadeh M, Philp T, Matthews. Transurethral vaporization of the prostate: a promising new technique. Br J Urol 1997; 79:186-189.
52. Kaplan SA, Santarosa RP, Te AE. Transurethral electrovaporisation of the prostate: one-year experience. Urology 1996; 48:876-881.
53. Te AE, Santarosa R, Kaplan SA. Electrovaporization of the prostate: electrosurgical modification of standard transurethral resection in 93 patients with benign hyperplasia. J Endourol 1997; 11:71-75.
54. Burney TL, Desautel MG, Badlani GH. Evaluation of transurethral vaporization of prostate with pressure-flow studies and other clinical measures. J Endourol 1996; 10:469-472.
55. max.
56. Cetinkaya M, Ulusoy E, Adsan Ö. Saglam H. Öztürk B, Basay S. Comparative early results of transurethral electroresection and transurethral electrovaporisation in benign prostatic hyperplasia. Br J Urol 1996; 78:901-903.
57. Ekengren J, Hahn RG. Complications during transurethral vaporization of the prostate. Urology 1996; 48:424-427.
58. Michel MS, Köhrmann KU, Weber A, Krautschick AW, Steidler A, Alken P. Standardized comparison of laser-vaporization, electrovaporization and modified electro-loop resection [Abstract]. J Urol 1997; 157:436.
59. Kabalin JN. Laser prostatectomy is a safer, better operation than electrovaporisation of the prostate. Urology 1997; 49:160-165.
60. Kaplan SA. Electrovaporisation of the prostate: durable modality or passing fad? Urology 1997; 49:157-159.
61. Cresswell MD, Cass CB, Fraundorfer MR, Gilling PJ. Homium:YAG laser resection of the prostate: preliminary experience with the first 400 cases. NZ Med J 1997; 110:76-78.
62. Gilling PJ, Cass CB, Cresswell MD, Malcolm AR, Fraundorfer MR. The use of the holmium laser in the treatment of benign prostatic hyperplasia. J Endourol 1996; 10:459-461.
63. Kabalin JN. Holmium:YAG laser prostatectomy: results of U.S. pilot study. J Endourol 1996; 10:453-457.
64. Perlmutter AP. Advances in electrosurgical techniques. Curr Opin Urol 1997; 7:21-24. This article describes electrosurgical principles and laboratory and initial clinical experience with loop electrodes that have greater masses and dimensions than standard tungsten loops